- Home
- SPH vs PHVS Comparison
SPH vs PHVS Comparison
Compare SPH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPH | PHVS |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.7B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPH | PHVS |
|---|---|---|
| Price | $18.06 | $24.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $39.44 |
| AVG Volume (30 Days) | 159.2K | ★ 271.8K |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | ★ 42.10 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $1,432,518,000.00 | N/A |
| Revenue This Year | $2.06 | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $11.27 | ★ N/A |
| Revenue Growth | ★ 7.94 | N/A |
| 52 Week Low | $17.30 | $11.51 |
| 52 Week High | $22.24 | $29.80 |
Technical Indicators
Market Signals| Indicator | SPH | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 35.15 | 48.84 |
| Support Level | $18.32 | $23.62 |
| Resistance Level | $18.81 | $28.43 |
| Average True Range (ATR) | 0.36 | 1.57 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 3.26 | 29.52 |
Price Performance
Historical ComparisonAbout SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.